A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper

被引:8
|
作者
Laurens, Matthew B. [1 ]
Sirima, Sodiomon B. [2 ]
Rotrosen, Elizabeth T. [1 ,4 ]
Siribie, Mohamadou [2 ]
Tiono, Alfred [2 ]
Ouedraogo, Alphonse [2 ]
Liang, Yuanyuan [3 ]
Jamka, Leslie P. [1 ]
Kotloff, Karen L. [1 ]
Neuzil, Kathleen M. [1 ]
机构
[1] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, 685 W Baltimore St Room 480, Baltimore, MD 21201 USA
[2] Grp Rech Act Sante, Ouagadougou, Burkina Faso
[3] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA
[4] Boston Univ, Sch Med, Boston, MA 02215 USA
基金
比尔及梅琳达.盖茨基金会;
关键词
child; typhoid-paratyphoid vaccines; Burkina Faso; immunogenicity; conjugate; ACELLULAR PERTUSSIS-VACCINE; ENTERICA SEROVAR TYPHI; SUB-SAHARAN AFRICA; IMMUNE-RESPONSE; SALMONELLA; MULTICENTER;
D O I
10.1093/cid/ciy1104
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The recent Typhoid Fever Surveillance in Africa Program demonstrated an overall adjusted incidence of typhoid fever 2-3 times higher than previous estimates in Africa. Recently, a single-dose typhoid conjugate vaccine that allows infants as young as 6 months old to be vaccinated was prequalified by the World Health Organization (WHO). This Vi-based conjugate vaccine demonstrated robust immunogenicity after 1 dose in infants and children 6 through 23 months of age in India with no safety signal, and is currently being tested for the first time on the African continent in Malawi. The WHO Strategic Advisory Group of Experts recommends studies to evaluate co-administering Vi-typhoid conjugate vaccine (Vi-TCV) with routine childhood vaccines in typhoid-endemic countries. The Burkina Faso immunization schedule includes yellow fever vaccine (YFV) at 9 months and meningococcal A conjugate vaccine (MCV-A) at 15 months, in addition to measles-rubella vaccine at both 9 and 15 months. Co-administration testing of Vi-TCV with these routine vaccinations will provide the data needed to support large-scale uptake of Vi-TCV in sub-Saharan Africa. A randomized, controlled, Phase II trial of Vi-TCV co-administration with the vaccinations routinely given at 9 and 15 months of age is planned in Burkina Faso. The overall aim is to assess the safety and immunogenicity of Vi-TCV when co-administered with YFV at 9 months of age and with MCV-A at 15 months of age. A total of 250 participants (100 infants aged 9-11 months and 150 children aged 15-23 months) will be enrolled. Clinical Trials Registration. NCT03614533. The World Health Organization recently prequalified a single-dose, typhoid conjugate vaccine for children as young as 6 months of age. A randomized, controlled clinical trial will assess the safety and immunogenicity of co-administration with routine childhood vaccines in Burkina Faso.
引用
收藏
页码:S59 / S66
页数:8
相关论文
共 50 条
  • [21] Efficacy, safety and immunogenicity of live attenuated varicella vaccine in healthy children in China: double-blind, randomized, placebo-controlled clinical trial
    Hao, B.
    Chen, Z.
    Zeng, G.
    Huang, L.
    Luan, C.
    Xie, Z.
    Chen, J.
    Bao, M.
    Tian, X.
    Xu, B.
    Wang, Y.
    Wu, J.
    Xia, S.
    Yuan, L.
    Huang, J.
    CLINICAL MICROBIOLOGY AND INFECTION, 2019, 25 (08) : 1026 - 1031
  • [22] Effect of zinc supplementation on growth in West African children:: a randomized double-blind placebo-controlled trial in rural Burkina Faso
    Müller, O
    Garenne, M
    Reitmaier, P
    van Zweeden, AB
    Kouyate, B
    Becher, H
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2003, 32 (06) : 1098 - 1102
  • [23] SAFETY AND IMMUNOGENICITY OF AGS-V, A MOSQUITO SALIVA PEPTIDE VACCINE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1 TRIAL
    Manning, Jessica
    Oliveira, Fabiano
    Coutinho-Abreu, Iliano
    Herbert, Samantha
    Meneses, Claudio
    Kamhawi, Shaden
    Baus, Holly
    Han, Alison
    Czajkowski, Lindsay
    Rosas, Luz
    Cervantes-Medina, Adriana
    Athota, Rani
    Reed, Susan
    Fernandez, Ana
    Pleguezuelos, Olga
    Stoloff, Gregory
    Valenzuela, Jesus
    Memoli, Matthew
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2018, 99 (04): : 213 - 213
  • [24] Evaluation of a probiotics, Bifidobacterium breve BBG-01, for enhancement of immunogenicity of an oral inactivated cholera vaccine and safety: A randomized, double-blind, placebo-controlled trial in Bangladeshi children under 5 years of age
    Matsuda, F.
    Chowdhury, M. I.
    Saha, A.
    Asahara, T.
    Nomoto, K.
    Tarique, A. A.
    Ahmed, T.
    Nishibuchi, M.
    Cravioto, A.
    Qadri, F.
    VACCINE, 2011, 29 (10) : 1855 - 1858
  • [25] SAFETY AND IMMUNOGENICITY OF AGS-V, A MOSQUITO SALIVA PEPTIDE VACCINE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1 TRIAL
    Manning, Jessica E.
    Kamhawi, Shaden
    Oliveira, Fabiano
    Coutinho-Abreu, Iliano V.
    Meneses, Claudio
    Baus, Holly Ann
    Han, Alison
    Czajkowski, Lindsay
    Donaldson, Amanda
    Athota, Rani
    Reed, Susan
    Bristol, Tyler
    Rosas, Luz Angela
    Fernandez, Ana
    Pleguezuelos, Olga
    Stoloff, Gregory
    Valenzuela, Jesus
    Memoli, Matt
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 97 (05): : 365 - 365
  • [26] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial
    Guo, Wanshen
    Duan, Kai
    Zhang, Yuntao
    Yuan, Zhiming
    Zhang, Yan-Bo
    Wang, Zejun
    Zhao, Dongyang
    Zhang, Huajun
    Xie, Zhiqiang
    Li, Xinguo
    Peng, Cheng
    Zhang, Wei
    Yang, Yunkai
    Chen, Wei
    Gao, Xiaoxiao
    You, Wangyang
    Wang, Xue-Wei
    Shi, Zhengli
    Wang, Yanxia
    Yang, Xu-Qin
    Zhang, Lianghao
    Huang, Lili
    Wang, Qian
    Lu, Jia
    Yang, Yong-Li
    Guo, Jing
    Zhou, Wei
    Wan, Xin
    Wu, Cong
    Wang, Wenhui
    Du, Jianhui
    Nian, Xuanxuan
    Li, Xing-Hang
    Huang, Shihe
    Shen, Shuo
    Xia, Shengli
    Pan, An
    Yang, Xiaoming
    ECLINICALMEDICINE, 2021, 38
  • [27] A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years
    Schwarz, T. F.
    Flamaing, J.
    Rumke, H. C.
    Penzes, J.
    Juergens, C.
    Wenz, A.
    Jayawardene, D.
    Giardina, P.
    Emini, E. A.
    Gruber, W. C.
    Schmoele-Thoma, B.
    VACCINE, 2011, 29 (32) : 5195 - 5202
  • [28] Safety and immunogenicity of the group B streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trial
    Gonzalez-Miro, Majela
    Pawlowski, Andrzej
    Lehtonen, Janne
    Cao, Duojia
    Larsson, Sara
    Darsley, Michael
    Kitson, Geoff
    Fischer, Per B.
    Johansson-Lindbom, Bengt
    ISCIENCE, 2023, 26 (03)
  • [29] Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China
    Hu, Yuemei
    Shao, Ming
    Hu, Yuansheng
    Liang, Qi
    Jia, Ningning
    Chu, Kai
    Xu, Li
    Li, Jing
    Li, Changgui
    Zhu, Fengcai
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (07) : 1691 - 1698
  • [30] Immunogenicity and safety assessment of a trivalent, inactivated split influenza vaccine in Korean children: Double-blind, randomized, active-controlled multicenter phase III clinical trial
    Han, Seung Beom
    Rhim, Jung-Woo
    Shin, Hye Jo
    Lee, Soo Young
    Kim, Hyun-Hee
    Kim, Jong-Hyun
    Lee, Kyung-Yil
    Ma, Sang Hyuk
    Park, Joon Soo
    Kim, Hwang Min
    Kim, Chun Soo
    Kim, Dong Ho
    Choi, Young Youn
    Cha, Sung-Ho
    Hong, Young Jin
    Kang, Jin Han
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (05) : 1094 - 1101